Abstract | IMPORTANCE OF THE FIELD: It is important to treat patients with Cushing's disease as rapidly as possible to limit both the mortality and morbidity of the disease. Pituitary surgery remains the treatment of choice, but the rate of cure at long-term follow-up is suboptimal and recurrence rates are high. If surgery fails or relapse occurs, no treatment has proven to be fully satisfactory. Currently available medical therapies are considered a transient and palliative treatment. However, recently there has been renewed interest in medical therapy due to new insights in pathogenetic mechanisms of corticotroph pituitary tumors. AREAS COVERED IN THIS REVIEW: WHAT THE READER WILL GAIN: The reader should gain an understanding of preclinical and clinical data supporting the potential use of pasireotide in patients with Cushing's disease. TAKE HOME MESSAGE:
|
Authors | Giorgio Arnaldi, Marco Boscaro |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 19
Issue 7
Pg. 889-98
(Jul 2010)
ISSN: 1744-7658 [Electronic] England |
PMID | 20533892
(Publication Type: Journal Article, Review)
|
Chemical References |
- Receptors, Somatostatin
- Somatostatin
- Adrenocorticotropic Hormone
- pasireotide
|
Topics |
- Adrenocorticotropic Hormone
(metabolism)
- Animals
- Clinical Trials, Phase III as Topic
- Cushing Syndrome
(drug therapy, etiology, metabolism)
- Drug Evaluation, Preclinical
- Humans
- Protein Binding
- Receptors, Somatostatin
(agonists)
- Somatostatin
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
- Treatment Outcome
|